CN115956676B - Plant source compound combination for preventing and treating motion sickness - Google Patents
Plant source compound combination for preventing and treating motion sickness Download PDFInfo
- Publication number
- CN115956676B CN115956676B CN202211660246.2A CN202211660246A CN115956676B CN 115956676 B CN115956676 B CN 115956676B CN 202211660246 A CN202211660246 A CN 202211660246A CN 115956676 B CN115956676 B CN 115956676B
- Authority
- CN
- China
- Prior art keywords
- motion sickness
- mice
- plant source
- source compound
- compound combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000003152 motion sickness Diseases 0.000 title claims abstract description 40
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 claims abstract description 18
- MHVJRKBZMUDEEV-APQLOABGSA-N (+)-Pimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@](C=C)(C)C=C2CC1 MHVJRKBZMUDEEV-APQLOABGSA-N 0.000 claims abstract description 9
- MHVJRKBZMUDEEV-UHFFFAOYSA-N (-)-ent-pimara-8(14),15-dien-19-oic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)C=C1CC2 MHVJRKBZMUDEEV-UHFFFAOYSA-N 0.000 claims abstract description 9
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 claims abstract description 9
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims abstract description 9
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 9
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 claims abstract description 9
- NIKHGUQULKYIGE-OTCXFQBHSA-N ent-kaur-16-en-19-oic acid Chemical compound C([C@@H]1C[C@]2(CC1=C)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 NIKHGUQULKYIGE-OTCXFQBHSA-N 0.000 claims abstract description 9
- OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 claims abstract description 9
- XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 claims abstract description 9
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000008800 isorhamnetin Nutrition 0.000 claims abstract description 9
- NIKHGUQULKYIGE-UHFFFAOYSA-N kaurenoic acid Natural products C1CC2(CC3=C)CC3CCC2C2(C)C1C(C)(C(O)=O)CCC2 NIKHGUQULKYIGE-UHFFFAOYSA-N 0.000 claims abstract description 9
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims abstract description 9
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims abstract description 9
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 claims abstract 2
- VWXMLZQUDPCJPL-ZDHAIZATSA-N Rhodoxanthin Chemical compound CC\1=CC(=O)CC(C)(C)C/1=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C1\C(C)=CC(=O)CC1(C)C VWXMLZQUDPCJPL-ZDHAIZATSA-N 0.000 claims description 6
- VWXMLZQUDPCJPL-XPZLFLLQSA-N Rhodoxanthin Natural products O=C1C=C(C)/C(=C\C=C(/C=C/C=C(\C=C\C=C\C(=C/C=C/C(=C\C=C\2/C(C)=CC(=O)CC/2(C)C)/C)\C)/C)\C)/C(C)(C)C1 VWXMLZQUDPCJPL-XPZLFLLQSA-N 0.000 claims description 6
- 239000004216 Rhodoxanthin Substances 0.000 claims description 6
- VWXMLZQUDPCJPL-JCFHCUBBSA-N all-trans-Rhodoxanthin Natural products CC(=C/C=C/C(=C/C=C/1C(=CC(=O)CC1(C)C)C)/C)C=CC=CC(=CC=CC(=CC=C2/C(=CC(=O)CC2(C)C)C)C)C VWXMLZQUDPCJPL-JCFHCUBBSA-N 0.000 claims description 6
- 235000019246 rhodoxanthin Nutrition 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 50
- 241000196324 Embryophyta Species 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 241000208422 Rhododendron Species 0.000 abstract description 3
- 230000006400 anxiety behaviour Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000003542 behavioural effect Effects 0.000 abstract description 2
- 230000000284 resting effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 6
- 230000008925 spontaneous activity Effects 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 231100000877 autonomic nervous system dysfunction Toxicity 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a plant source compound combination for preventing and treating motion sickness. The plant source compound combination is prepared from pimaric acid, isorhamnetin, imperatorin, azalea, kaurenic acid, hyperoside and scopoletin. Animal behavioral experiment results show that the invention can effectively improve symptoms of motion sickness, regulate anxiety behavior and stress state of mice after motion sickness occurs, improve coordination ability of mice, prevent physical fatigue of mice, and is a healthy plant source medicine for preventing and treating motion sickness. The invention has the advantages of easily available raw materials, effective treatment of motion sickness, small toxic and side effects and good application value.
Description
Technical Field
The invention relates to a plant source compound combination for preventing and treating motion sickness, belonging to the technical field of medicines.
Background
Motion sickness refers to a multi-system physiological response of the human body to an inappropriate motor pattern stimulus. The physiological reactions include autonomic nerve reactions such as dizziness, emesis, cold sweat, pale complexion, etc., abnormal energy metabolism, fatigue, somnolence, etc. In modern society, people travel more and more vehicles, and motion sickness is increasingly serious. Motion sickness is also known by different names, such as air sickness, sea sickness, space sickness, etc., due to different motion environments.
The incidence of motion sickness is extremely high, and about 85% of the population experience symptoms of motion sickness. Although motion sickness does not threaten the life of a human body, the motion sickness can affect the traveling quality and daily work efficiency of people when serious.
At present, various Western medicines for treating motion sickness exist, but some medicines have certain side effects, such as sleepiness, dry mouth, gastrointestinal and respiratory secretions reduction and the like caused by taking diphenhydramine, and the medicines are not suitable for long-term administration. The plant compound used as both medicine and food has various bioactive substances, good curative effect and small toxic and side effects when treating motion sickness. Therefore, there is a need to provide a combination of plant-derived compounds for the control of motion sickness.
Disclosure of Invention
The invention aims to provide a plant source compound combination for preventing and treating motion sickness, wherein the plant source compound is from fennel which is a medicinal and edible plant of the Umbelliferae, has small toxic and side effects and has good application value.
The plant source compound combination for preventing and treating motion sickness provided by the invention is prepared from pimaric acid, isorhamnetin, imperatorin, rhodoxanthin, kaurenic acid, hyperin and scopoletin.
Specifically, the plant source compound combination comprises the following components in parts by mass:
1 to 5 parts of pimaric acid; 5-10 parts of isorhamnetin; 5-10 parts of imperatorin; 5-10 parts of rhodoxanthin; 1 to 5 percent of kaurenoic acid; 1 to 5 portions of hyperin; scopoletin 1-5.
Preferably, the plant source compound combination comprises the following components in parts by mass:
pimaric acid 4, isorhamnetin 8, imperatorin 8, azalea acid 8, kaurenoic acid 4, hyperin 4, scopoletin 4, e.g., 4mg pimaric acid, 8mg isorhamnetin, 8mg imperatorin, 8mg azalea, 4mg kaurenoic acid, 4mg hyperin, 4mg scopoletin.
The preparation method of the plant source compound combination comprises the following steps:
dissolving each component in the plant source compound combination by adopting an aqueous solution (such as 0.5 wt%) of sodium carboxymethylcellulose, mixing, concentrating, and vacuum freeze-drying the obtained filtrate to obtain powder.
The animal behavioral experimental results show that the plant source compound combination can effectively improve symptoms of motion sickness, regulate anxiety behaviors and stress states of mice after the motion sickness occurs, improve coordination ability of the mice, prevent physical fatigue of the mice, and is a healthy plant source medicine for preventing and treating the motion sickness.
The plant source compound combination provided by the invention is used for treating motion sickness. The research of the invention shows that the combination can produce therapeutic effect on motion sickness without side effect; and the raw materials are easy to obtain, and the method has good application value.
Drawings
FIG. 1 is a graph showing the effect of a combination of plant-derived compounds of the invention on the vignetting response index score of each group of mice.
Fig. 2 shows the effect of the plant-derived compound combination of the present invention on spontaneous activity of each group of mice, wherein, fig. 2, panel a shows the number of erection times of the mice, fig. 2, panels B and C show the number of crossing times of the square of the mice, the number of crossing times of the central lattice, respectively, and fig. 2, panel D shows the resting time of the mice.
Detailed Description
The experimental methods used in the following examples are conventional methods unless otherwise specified.
Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
Example 1 plant-derived Compound combinations
Weighing respectively: 4mg of pimaric acid, 8mg of isorhamnetin, 8mg of imperatorin, 8mg of rhodoxanthin, 4mg of kaurenoic acid, 4mg of hyperin and 4mg of scopoletin.
Dissolving each part of raw materials by using 0.5% sodium carboxymethylcellulose, fully dissolving by using a vortex instrument, pouring each part of obtained solution into a container, stirring, concentrating by using a rotary evaporator at 50 ℃, collecting concentrated solution, and performing vacuum freeze drying to obtain powder for later use.
Example 2 Effect of plant-derived Compound combinations on the vignetting response index score of groups of mice
1. Medicaments and agents
Test article: the plant source Compound combinations prepared in example 1
Positive control: diphenhydramine
2. Experimental animal
Male Kunming mice raised in the animal-grade SPF-grade barrier system, 6-8 weeks old, weighing 18-25g, were purchased from Henan province laboratory animal center. Placing in a dry and clean plastic cage, and feeding standard experimental animal feed with free water.
3. Experimental method
After 7 days of adaptive rearing, the mice were randomly grouped into 8 groups. The experiments set up three dose groups of a blank control group (NC), an motion sickness model group (MS), a positive control group (DIP) and a plant source compound combination low (CM-L), medium (CM-M) and high (CM-H).
Blank control (NC): 10ml/kg bw 0.5% sodium carboxymethylcellulose
Motion sickness Model Set (MS): 10ml/kg bw 0.5% sodium carboxymethylcellulose
Positive control group (DIP): 10mg/kg bw diphenhydramine
Combination of plant-derived compounds low dose group (CM-L): 10mg/kg bw
Dose group (CM-M) in combination of plant-derived compounds: 20mg/kg bw
High dose group of botanical compounds (CM-H): 40mg/kg bw
The mice were subjected to gastric lavage administration before the start of the experiment, and after 30min of administration, the groups except NC group were placed in an motion sickness molding device for molding for 1h. Mice were placed on either side of the device shaft and started to rotate clockwise until the angular velocity reached 240 °/s 2 Then decelerating to a speed of 0 DEG/s 2 The device is again rotated counter-clockwise in the same way, without pausing in the middle. Angular acceleration is constant at 40 DEG/s 2 . The NC group mice are placed in a squirrel cage beside the device, the environmental conditions are kept consistent during molding, and after each molding is finished, the device and the organic glass box are sprayed and wiped by using an alcohol watering can, so that the smell is prevented from interfering the experimental result.
Since rodents do not have the ability to vomit, when motion sickness occurs, mice can develop a series of symptoms of autonomic nervous system dysfunction such as standing hair, trembling, defecation and urination. The change of the motion sickness index has good correlation with the severity of the gastrointestinal reaction caused by the mice exposed to the acceleration stimulus, so the change of the motion sickness index can be used as a judgment index of the severity of the motion sickness of the mice.
The vignetting response index scoring criteria are shown in table 1.
TABLE 1 dizziness response index scoring criteria
4. Experimental results
The halo reaction is developed immediately after the molding of each group of mice is completedAnd (5) evaluating an index. The experimental results obtained are shown in fig. 1, in which, ** P<0.01 is compared with the NC group, # P<0.05 was compared to the MS group, ## P<0.01 was compared to MS group (n=8).
As can be seen from fig. 1, after the rotation stimulation, the vignetting index score of the mice in the MS group is significantly higher than that of the mice in the NC group, and the rotation can cause the dysfunction of the autonomic nervous system of the mice. After the plant source compound is combined by gastric lavage, the CM-M group and the CM-H group can obviously reduce the vignetting response index of mice, relieve the autonomic nervous symptoms of mice and show obvious anti-motion sickness effect.
Example 3 Effect of a combination of plant-derived Compounds on spontaneous locomotor activity in groups of mice
The open field test is an animal behavioral test which can be used for detecting spontaneous activity conditions of experimental animals, and the spontaneous activity, anxiety and stress conditions of mice can be evaluated by one test, so that the results can reflect the change of central nervous system excitability, and symptoms such as reaction retardation and the like after the motion sickness occurs are similar to the change.
The open field experiment is carried out in an open field experiment box, a square box and the bottom of the square box is divided into 25 small square grids with the same size. During experiments, the mice are gently placed along a corner wall of the open field box, and are allowed to freely move in the open field box for 5 minutes and recorded by video. The environment was kept quiet and dim at the time of the experiment. The number of square crossing times and central square crossing times of the mice within 5 minutes are counted to reflect the autonomous behavior of the mice, and the number of standing times and resting time of the mice are counted to reflect the anxiety and stress degree of the mice.
Animal experiments were performed in the same manner as in example 2 using the plant source compound combinations prepared in example 1.
The spontaneous activity behavior experiment of the mice is carried out immediately after the modeling of each group of mice is completed. The experimental results obtained are shown in fig. 2, wherein, graph a shows the number of erection times of the mice, **** P<0.0001 in contrast to the NC group, # P<0.05 was compared to the MS group, ## P<0.01 compared to MS group (n=8); the graph B and the graph C are the crossing times of the square lattice of the mice and the crossing times of the central lattice respectively, **** P<0.0001 andthe NC group is compared with the group, # P<0.05 vs MS group (n=8); panel D shows the resting time of the mice, **** P<0.0001 in contrast to the NC group, ## P<0.01 was compared to MS group (n=8).
As can be seen from fig. 2, the number of square crossings, the number of central square crossings and the number of erections of the MS group mice were significantly reduced and the resting time was significantly increased as compared to the NC group mice. The results indicate that MS group mice exhibit pronounced anxiety behavior and reduced voluntary activity behavior. The DIP mice showed a decrease in the number of erections and inter-square crosses and an increase in resting time compared to the MS mice, probably due to side effects of the positive control DIP, inhibition of the central nervous system and anxiety. After the plant source compound combination is given, the number of times of crossing of the check of the mice, the number of times of crossing of the central check and the number of times of erection of the CM-H group are obviously higher than those of the MS group, the resting time is obviously lower than that of the MS group, and the action effect is higher than that of the CM-M group. The research shows that CM can reduce anxiety and stress of mice, increase spontaneous activity of mice, and has obvious anti-motion sickness effect.
In conclusion, animal experiment results show that the plant source compound combination can reduce the vignetting response index of mice, increase the erection times, the square crossing times and the central lattice crossing times of the mice after rotation stimulation, reduce the resting time of the mice, lighten anxiety and stress of the mice and increase the spontaneous activity behaviors of the mice, and the combination can be used for effectively treating motion sickness.
Claims (4)
1. A plant source compound composition for preventing and treating motion sickness is prepared from pimaric acid, isorhamnetin, imperatorin, rhodoxanthin, kaurenic acid, hyperoside and scopoletin;
the plant source compound combination comprises the following components in parts by mass:
1 to 5 parts of pimaric acid; 5-10 parts of isorhamnetin; 5-10 parts of imperatorin; 5-10 parts of rhodoxanthin; 1 to 5 percent of kaurenoic acid; 1 to 5 portions of hyperin; scopoletin 1-5.
2. The plant-derived compound combination according to claim 1, wherein: the plant source compound combination comprises the following components in parts by mass:
pimaric acid 4, isorhamnetin 8, imperatorin 8, rhodoxanthin 8, kaurenoic acid 4, hyperin 4, scopoletin 4.
3. A method of preparing a combination of plant-derived compounds according to claim 1 or 2, comprising the steps of:
dissolving each component in the plant source compound combination by adopting an aqueous solution of sodium carboxymethyl cellulose, mixing, concentrating, and vacuum freeze-drying the obtained concentrated solution to prepare powder.
4. Use of a combination of compounds of plant origin according to claim 1 or 2 for the preparation of a medicament for the prevention and treatment of motion sickness.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211660246.2A CN115956676B (en) | 2022-12-23 | 2022-12-23 | Plant source compound combination for preventing and treating motion sickness |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211660246.2A CN115956676B (en) | 2022-12-23 | 2022-12-23 | Plant source compound combination for preventing and treating motion sickness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115956676A CN115956676A (en) | 2023-04-14 |
| CN115956676B true CN115956676B (en) | 2024-03-01 |
Family
ID=87354435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211660246.2A Active CN115956676B (en) | 2022-12-23 | 2022-12-23 | Plant source compound combination for preventing and treating motion sickness |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115956676B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112675280A (en) * | 2021-01-14 | 2021-04-20 | 韦燕玲 | Composition for preventing and treating carsickness and preparation method thereof |
| CN114948980A (en) * | 2022-06-09 | 2022-08-30 | 山西大学 | Pharmaceutical composition for preventing and/or treating anxiety insomnia and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3096692A1 (en) * | 2018-04-17 | 2019-10-24 | Poviva Corp. | Lipophilic active agent infused compositions with reduced food effect |
-
2022
- 2022-12-23 CN CN202211660246.2A patent/CN115956676B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112675280A (en) * | 2021-01-14 | 2021-04-20 | 韦燕玲 | Composition for preventing and treating carsickness and preparation method thereof |
| CN114948980A (en) * | 2022-06-09 | 2022-08-30 | 山西大学 | Pharmaceutical composition for preventing and/or treating anxiety insomnia and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| 侯秋莉 等.东莨菪内酯的生物活性研究进展.天然产物研究与开发.2013,第25卷(第10期),1431-1467. * |
| 党凯茹 等.高效液相色谱-二极管阵列检测器法测定食用土当归总有机酸中贝壳杉烯酸及海松酸含量.中国药业.2018,第27卷(第2期),16-19. * |
| 杨菁 等.食用土当归总有机酸的抗炎镇痛作用.中成药.2016,第9卷(10),37-40. * |
| 钟广亮 等.晕车影响因素及对策探讨.汽车实用技术.2020,(第5期),170-176. * |
| 齐璐 等.晕动病的中医病因病机和治疗进展.中国中医急症.2011,第20卷(第10期),1652-1653. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115956676A (en) | 2023-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101803069B1 (en) | Composition for improving livestock immunity comprising probiotics as effective component | |
| CN104606701A (en) | Air refreshing deodorant capable of releasing element negative ions | |
| CN105148059A (en) | Plant oil external liniment capable of repelling mosquitos and preparation method thereof | |
| CN115956676B (en) | Plant source compound combination for preventing and treating motion sickness | |
| CN107789654A (en) | Discharge the air freshener of element anion | |
| JPH08502030A (en) | Biocidal composition containing mustard seed plant extract | |
| CN108522851A (en) | Eucommia leaf extract and its application in preparing the feed addictive for improving meat rabbit growth performance | |
| JPH03198747A (en) | Disease-preventive feed and feed additive for cattle and pig | |
| RU2388481C2 (en) | Treatment-and-preventive agent for young farm animals; and method for prevention of respiratory diseases among calve and its application | |
| Kobayashi et al. | Accumulation of cadmium in organs of mice fed on cadmium-polluted rice | |
| RU2461385C1 (en) | Method of preventing respiratory diseases in calves | |
| CN114652767B (en) | Dairy cow nipple medicated bath agent and preparation method thereof | |
| CN108066278B (en) | Gynecological gel containing chitosan oligosaccharide and preparation method thereof | |
| RU2297214C2 (en) | Method for preventing and treating gastrointestinal diseases in animals and poultry | |
| CN102847160B (en) | Compound quinolone injection for livestock, and preparation method thereof | |
| JPH0656689A (en) | Preventing and treating composition for infectious diarrhea | |
| RU2370274C1 (en) | Bioactive veterinary drug and method of non-specific resistanse improval for calves using drug | |
| RU2778778C1 (en) | Ointment for the treatment of burns and infected wounds and a method for treatment with its use | |
| DE10163602A1 (en) | Composition for treating allergic diseases, e.g. dermatitis, psoriasis, asthma or allergic rhinitis, comprises parasitic worm preparation | |
| RU2418605C1 (en) | Method of treating respiratory diseases in calves | |
| RU2524664C1 (en) | Method of prevention of mass gastrointestinal and respiratory diseases of suckling pigs | |
| RU2746146C1 (en) | Method for increasing the growth rate of newborn calves | |
| RU2070409C1 (en) | Drug for treatment of mastitis in milking animals | |
| RU2423996C1 (en) | Method of phytopreparation therapy of gastrointestinal diseases in calves | |
| WO2018063025A1 (en) | Iron compound-based pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |